Shankar Haripriya, Murugappan Swaminathan, Kim Soochong, Jin Jianguo, Ding Zhongren, Wickman Kevin, Kunapuli Satya P
Department of Physiology, Temple University, 3420 N Broad St, Philadelphia, PA 19140, USA.
Blood. 2004 Sep 1;104(5):1335-43. doi: 10.1182/blood-2004-01-0069. Epub 2004 May 13.
The role of the G(i)-coupled platelet P2Y(12) receptor in platelet function has been well established. However, the functional effector or effectors contributing directly to alphaIIbbeta3 activation in human platelets has not been delineated. As the P2Y(12) receptor has been shown to activate G protein-gated, inwardly rectifying potassium (GIRK) channels, we investigated whether GIRK channels mediate any of the functional responses of the platelet P2Y(12) receptor. Western blot analysis revealed that platelets express GIRK1, GIRK2, and GIRK4. In aspirin-treated and washed human platelets, 2 structurally distinct GIRK inhibitors, SCH23390 (R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride) and U50488H (trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(pyrrolidinyl)cyclohexyl] benzeneacetamide methanesulfonate), inhibited adenosine diphosphate (ADP)-, 2-methylthioADP (2-MeSADP)-, U46619-, and low-dose thrombin-mediated platelet aggregation. However, the GIRK channel inhibitors did not affect platelet aggregation induced by high concentrations of thrombin, AYPGKF, or convulxin. Furthermore, the GIRK channel inhibitors reversed SFLLRN-induced platelet aggregation, inhibited the P2Y(12)-mediated potentiation of dense granule secretion and Akt phosphorylation, and did not affect the agonist-induced G(q)-mediated platelet shape change and intracellular calcium mobilization. Unlike AR-C 69931MX, a P2Y(12) receptor-selective antagonist, the GIRK channel blockers did not affect the ADP-induced adenlylyl cyclase inhibition, indicating that they do not directly antagonize the P2Y(12) receptor. We conclude that GIRK channels are important functional effectors of the P2Y(12) receptor in human platelets.
G(i) 偶联的血小板 P2Y(12) 受体在血小板功能中的作用已得到充分证实。然而,直接促成人类血小板中 αIIbβ3 激活的功能效应器尚未明确。由于 P2Y(12) 受体已被证明可激活 G 蛋白门控内向整流钾通道(GIRK 通道),我们研究了 GIRK 通道是否介导血小板 P2Y(12) 受体的任何功能反应。蛋白质印迹分析显示血小板表达 GIRK1、GIRK2 和 GIRK4。在阿司匹林处理并洗涤过的人类血小板中,两种结构不同的 GIRK 抑制剂 SCH23390(R(+)-7-氯-8-羟基-3-甲基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓盐酸盐)和 U50488H(反式-(+/-)-3,4-二氯-N-甲基-N-[2-(吡咯烷基)环己基]苯乙酰胺甲磺酸盐)抑制二磷酸腺苷(ADP)、2-甲基硫代 ADP(2-MeSADP)、U46619 和低剂量凝血酶介导的血小板聚集。然而,GIRK 通道抑制剂不影响高浓度凝血酶、AYPGKF 或convulxin 诱导的血小板聚集。此外,GIRK 通道抑制剂可逆转 SFLLRN 诱导的血小板聚集,抑制 P2Y(12) 介导的致密颗粒分泌增强和 Akt 磷酸化,且不影响激动剂诱导的 G(q) 介导的血小板形状变化和细胞内钙动员。与 P2Y(12) 受体选择性拮抗剂 AR-C 69931MX 不同,GIRK 通道阻滞剂不影响 ADP 诱导的腺苷酸环化酶抑制,表明它们不直接拮抗 P2Y(12) 受体。我们得出结论,GIRK 通道是人类血小板中 P2Y(12) 受体的重要功能效应器。